862269-71-4

Upstream product

• 56401-28-6 [2-hydroxyimino-3-(4-hydroxyphenyl)]propionic acid 

Downstream Products

• 1383447-50-4 (E)-tert-butyl 2-((2-(3-(3-bromo-4-hydroxyphenyl)-2-(hydroxyimino)propanamido)ethyl)disulfanyl)ethylcarbamate 
• 1395313-10-6 (E)-3-(3-bromo-4-hydroxyphenyl)-N-(2-((2-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)ethyl)disulfanyl)ethyl)-2-(hydroxyimino)propanamide 
• 73348-21-7 2-(3-bromo-4-hydroxyphenyl)acetonitrile 
• 109152-30-9 psammaplin A 
• 1256735-92-8 ((E)-N-3-(3-bromo-4-hydroxyphenyl)-2-oximidopropionyl-N'-ethoxyoxalyl)cystamine 

Relevant academic research and scientific papers

Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors

Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivatives and HDAC inhibitors. To exploit this synergy in a single active compound, we designed new dual-acting multivalent molecules simultaneously targeting topoisomerase I and HDAC. In particular, a selected compound containing a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.